The short version of freeze-thaw cycle fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-11 and is reviewed periodically as new material appears.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Acanthamoeba infection Amebiasis cutis Ant sting Arachnidism Baker's itch Balamuthia infection Bedbug infestation (bedbug bite, cimicosis) Bee and wasp stings Blister beetle dermatitis Bombardier beetle burn Bristleworm sting Centipede bite Cheyletiella dermatitis Chigger bite Coolie itch Copra itch Coral dermatitis Creeping eruption (cutaneous larva migrans) Cutaneous leishmaniasis (Aleppo boil, Baghdad boil, bay sore, Biskra button, Chiclero ulcer, Delhi boil, Kandahar sore, Lahore sore, leishmaniasis tropica, oriental sore, pian bois, uta) Cysticercosis cutis Demodex folliculitis, usually caused by the Demodex folliculorum mite Dogger Bank itch Dracunculiasis (dracontiasis, guinea worm disease, Medina worm) Echinococcosis (hydatid disease) Elephantiasis tropica (elephantiasis arabum) Elephant skin Enterobiasis (oxyuriasis, pinworm infection, seatworm infection) Erisipela de la costa Feather pillow dermatitis Funnel web spider bite Gamasoidosis Gnathostomiasis (larva migrans profundus) Grain itch (barley itch, mattress itch, prairie itch, straw itch) Grocer's itch Head lice infestation (cooties, pediculosis capitis) Hookworm disease (ancylostomiasis, ground itch, necatoriasis, uncinariasis) Human trypanosomiasis Hydroid dermatitis Irukandji syndrome Jellyfish dermatitis Ked itch Larva currens Latrodectism (widow spider bite) Leech bite Leopard skin Lepidopterism (Caripito itch, caterpillar dermatitis, moth dermatitis) Lizard skin Loaiasis (Calabar swelling, fugitive swelling, loa loa, tropical swelling) Loxoscelism (brown recluse spider bite, necrotic cutaneous loxoscelism) Mal morando Millipede burn Mosquito bite Mucocutaneous leishmaniasis (espundia, leishmaniasis Americana) Myiasis Nairobi fly dermatitis (Kenya fly dermatitis, Nairobi eye) Nematode dermatitis Norwegian scabies (crusted scabies) Onchocerciasis Ophthalmia nodosa Paederus dermatitis Pediculosis corporis (pediculosis vestimenti, Vagabond's disease) Pediculosis pubis (crabs, phthirus pubis, phthirus pubis, pubic lice) Pneumocystosis (often classified as fungal) Portuguese man-of-war dermatitis Post-kala-azar dermal leishmaniasis (post-kala-azar dermatosis) Protothecosis Pulicosis (flea bites) Reduviid bite Scabies (itch mite infestation, seven-year itch) Scorpion sting Sea anemone dermatitis Seabather's eruption (sea lice) Sea urchin injury Seaweed dermatitis Snake bite Sowda Sparganosis Spider bite Stingray injury Swimmer's itch (cercarial dermatitis, schistosome cercarial dermatitis) Tarantula bite Tick bite Toxoplasmosis Trichinosis Trichomoniasis Tungiasis (bicho de pie, chigoe flea bite, jigger bite, nigua, pique) Visceral leishmaniasis (dumdum fever, kala-azar) Visceral schistosomiasis (bilharziasis) Viscerotropic leishmaniasis Wheat warehouse itch
=== Psychological impact === ED often has an impact on the emotional well-being of both males and their partners. Many males do not seek treatment due to feelings of embarrassment. About 75% of diagnosed cases of ED go untreated.
However, urea-formaldehyde resin itself has been suggested as appropriate for use in feed for some non-ruminants in at least one UN FAO report, suggesting its use as a binder in feed pellets in aquaculture. There is at least one report of inexpensively priced rice protein concentrate (feed grade) containing non-protein nitrogen being marketed for use in non-ruminants dating back to 2005. In a news item on its website, Jiangyin Hetai Industrial Co., Ltd. warned its customers of low-priced "PSEUDO rice protein" for sale in the market by another unnamed supplier, noting that the contaminant could be detected by analyzing the isoelectric point. It is not clear from that report whether the contaminant in that case was melamine or some other non-protein nitrogen source or whether any contaminated rice protein concentrate made it into the food supply at that time. On 18 April 2007, an ad was posted on the trading website Alibaba.com selling "Esb protein powder" in Xuzhou Anying's name. The product is said to be protein in nature and suitable for livestock and poultry feed, yet claims a crude protein content of 160–300%. It also mentions in passing the product makes use of "NPN" which is an acronym for non-protein nitrogen. Similar ads were placed on other websites, some dated as early as 31 October 2005. Products with similar descriptions were also sold as "EM bacterium active protein forage" by Shandong Binzhou Xinpeng Biosciences Company and "HP protein powder" by Shandong Jinan Together Biologic Technology Development Company.
Sources: en.wikipedia.org
With the exception of Russia, the Polish nation has the distinction among other Slavic peoples of having enjoyed independence as a part of various entities for several centuries prior to the advent of Pan-Slavism. After 1795, Revolutionary and Napoleonic France had influenced many Poles who sought the reconstitution of their existing country—particularly since France was a mutual enemy of Austria, Prussia, and also Russia. Russia's Pan-Slavic rhetoric had alarmed the Poles. Pan-Slavism was not fully embraced among Poles after the early period. Poland did nevertheless express solidarity with those of its fellow Slavic nations that had suffered oppression and were seeking independence. While Pan-Slavism as an ideology was inimical to Austro-Hungarian interests, Poles instead embraced the wide autonomy within the state and assumed a loyalist position towards the Habsburgs. Within the Austro-Hungarian polity, they were able to develop their national culture and preserve the Polish language, both of which were under threat in both German and Russian Empires. A Pan-Slavic federation was proposed, but on the condition that the Russian Empire would be excluded from such an entity. After Poland regained its independence (from Germany, Austria and Russia) in 1918, no internal faction considered Pan-Slavism as a serious alternative, viewing Pan-Slavism as Russification. During Poland's communist era, the USSR used Pan-Slavism as a propaganda tool to justify its control over the country.
=== Combined malonic and methylmalonic aciduria (CMAMMA) === In combined malonic and methylmalonic aciduria (CMAMMA), mutations in the ACSF3 gene impair the mitochondrial enzyme acyl-CoA synthetase family member 3 (ACSF3), disrupting the conversion of methylmalonic acid to methylmalonyl-CoA and its entry into the citric acid cycle. This leads to accumulation of methylmalonic acid, reduced methylmalonyl-CoA levels and decreased lysine methylmalonylation compared to healthy controls.
t is age of the sample, D* is number of atoms of the radiogenic daughter isotope in the sample, D0 is number of atoms of the daughter isotope in the original or initial composition, N(t) is number of atoms of the parent isotope in the sample at time t (the present), given by N(t) = N0e−λt, and λ is the decay constant of the parent isotope, equal to the inverse of the radioactive half-life of the parent isotope times the natural logarithm of 2. The equation is most conveniently expressed in terms of the measured quantity N(t) rather than the constant initial value No. To calculate the age, it is assumed that the system is closed (neither parent nor daughter isotopes have been lost from system), D0 either must be negligible or can be accurately estimated, λ is known to high precision, and one has accurate and precise measurements of D* and N(t). The above equation makes use of information on the composition of parent and daughter isotopes at the time the material being tested cooled below its closure temperature. This is well established for most isotopic systems. However, construction of an isochron does not require information on the original compositions, using merely the present ratios of the parent and daughter isotopes to a standard isotope. An isochron plot is used to solve the age equation graphically and calculate the age of the sample and the original composition.
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.